. 2023 Jul 28;12(7):1079–1089. doi: 10.21037/tau-22-684

Table 4. Multivariable analysis of factors associated with PFS and OS in the serum sample cohort.

Covariate	Level	PFS			OS
Covariate	Level	HR	95% CI	P	HR	95% CI	P
Metastatic disease at diagnosis	Yes	2.30	1.14–4.67	0.02	2.53	1.20–5.30	0.01
Metastatic disease at diagnosis	No	Reference	–	0.02	Reference	–	0.01
Low testosterone (<300 ng/dL)	Yes	0.89	0.54–1.48	0.66	0.98	0.58–1.67	0.95
Low testosterone (<300 ng/dL)	No	Reference	–	0.66	Reference	–	0.95
Received surgery	Yes	0.36	0.20–0.66	<0.01	0.40	0.21–0.78	<0.01
Received surgery	No	Reference	–	<0.01	Reference	–	<0.01
Received chemotherapy	Yes	1.53	0.79–2.95	0.21	1.01	0.52–1.95	0.98
Received chemotherapy	No	Reference	–	0.21	Reference	–	0.98
Received radiation therapy	Yes	0.70	0.42–1.18	0.18	0.62	0.35–1.10	0.10
Received radiation therapy	No	Reference	–	0.18	Reference	–	0.10

PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.